Navigation Links
Ohr Pharmaceutical Announces Addition of Dr. John Wroblewski to Ophthalmic Scientific Advisory Board
Date:8/7/2013

NEW YORK, Aug. 7, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (NasdaqCM: OHRP) today announced the addition of John J. Wroblewski M.D. to its Scientific Advisory Board ("SAB"). The board, comprised of leading retinal ophthalmology experts, advises the company on its clinical programs, regulatory strategy and provides strategic guidance to support the ongoing development of lead drug candidate Squalamine in multiple neovascular ophthalmic clinical indications, each with sizable commercial markets.

"Squalamine eye drops have the potential to significantly advance the treatment of wet-AMD through a unique mechanism of action which may provide distinct or additional benefits to the anti-VEGF agents currently used to treat these patients," stated Dr. John Wroblewski, retina specialist at Cumberland Valley Retina Consultants. "I am excited to be participating in the OHR-002 wet-AMD clinical trial and look forward to working closely with the Ohr team to evaluate Squalamine eye drops in additional ophthalmic indications where neovascularization plays an important role."

Irach B. Taraporewala, Ph.D., CEO of Ohr Pharmaceutical, commented, "We are delighted to be working with a thought leader and clinical researcher of Dr. Wroblewski's caliber. Our OHR-002 trial to evaluate Squalamine eye drops in wet-AMD continues to progress well, as evidenced by our recently announced completion of the halfway point in enrollment, and the expected availability of interim data in the second quarter of 2014.  We look forward to the contributions Dr. Wroblewski will make during this exciting time for Ohr Pharmaceutical."

John Joseph Wroblewski, M. D., is a board-certified ophthalmologist who has been treating diseases of the retina, macula, and vitreous for twenty-two years.  He is the senior partner of Cumberland Valley Retina Consultants located in Western Maryland and South-Central Pennsylvania.  Doctor Wroblewski is a graduate of the Moorfields Eye Hospital in London, England, and has served as a consultant and medical advisor to several ophthalmic pharmaceutical companies.  He has participated in the design of multiple clinical protocols and has been a Principal Investigator in twenty-three national clinical trials conducted over the past twelve years, all of which investigated the efficacy of different pharmaceutical agents in the treatment of exudative macular degeneration, retinal vein occlusion, and diabetic retinopathy.  Doctor Wroblewski has lectured nationally and internationally and is the founder and president of Retina Care International, a not-for-profit organization actively working since 2005 to help solve the diabetic retinopathy pandemic in the Yucatan Peninsula in Mexico.  Dr. Wroblewski received his M.D. from Georgetown University School of Medicine.

About Squalamine Eye Drops
Squalamine is an anti-angiogenic small molecule with a novel intracellular mechanism of action, which counteracts multiple growth factors implicated in the angiogenesis process. Ohr Pharmaceutical has developed a novel eye drop formulation of Squalamine for the treatment of wet-AMD, designed for self-administration, which may provide several potential advantages over the FDA approved current standards of care which require intravitreal injections directly into the eye.  The drug, using an intravenous administration in over 250 patients in Phase I and Phase II trials for the treatment of wet-AMD, showed favorable biological effect and maintained and improved visual acuity outcomes. In May 2012, the Squalamine Eye Drop program was granted Fast Track Designation by the U.S. FDA. A Phase II randomized, double blind, placebo controlled study (OHR-002) to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of wet-AMD is currently enrolling patients at more than twenty clinical sites in the U.S.

About Ohr Pharmaceutical Inc.
Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP) is a pharmaceutical company dedicated to the clinical development of new drugs for underserved therapeutic needs in large and growing markets. The Company is focused on advancing its pipeline products currently in phase II clinical development: Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration, and OHR/AVR118 for the treatment of cancer cachexia. Additional information on the Company can be found at www.ohrpharmaceutical.com.

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: 
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made only as the date thereof, and Ohr Pharmaceutical undertakes no obligation to update or revise the forward-looking statement whether as a result of new information, future events or otherwise. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the future success of our scientific studies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments, the financial resources available to us, and general economic conditions. For example, there can be no assurance that Ohr will be able to sustain operations for expected periods. Shareholders and prospective investors are cautioned that no assurance of the efficacy of pharmaceutical products can be claimed or assured until final testing; and no assurance or warranty can be made that the FDA or Health Canada will approve final testing or marketing of any pharmaceutical product. Ohr's most recent Annual Report and subsequent Quarterly Reports discuss some of the important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements for any reason.

Contact:
Investor Relations:
Tel: (877) 215-4813
Email: ir@ohrpharmaceutical.com

 


'/>"/>
SOURCE Ohr Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. China is an Attractive Option for Pharmaceutical Outsourcing due to Low Development Costs
2. Isis Pharmaceuticals to Present at the Canaccord Genuity 33rd Annual Growth Conference
3. Valeant Pharmaceuticals Reports 2013 Second Quarter Financial Results
4. Cadence Pharmaceuticals To Present At The 2013 Wedbush PacGrow Life Sciences Management Access Conference On August 13, 2013
5. Alexza Pharmaceuticals to Present at the 2013 Wedbush Life Sciences Management Access Conference
6. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
7. Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock
8. JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2013 FINANCIAL RESULTS
9. Cumberland Pharmaceuticals Reports Second Quarter Financial Results
10. Inovio Pharmaceuticals Responds to Market Activity
11. UPCOMING DEADLINE: Levi & Korsinsky Notifies Investors with Losses on Their Investment in Vanda Pharmaceuticals, Inc. of Class Action Lawsuit and the Deadline of August 24, 2013 to Seek a Lead Plaintiff Position
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... ... , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business ... to $12 an hour by 2020 and then adjusting it yearly to increase at the ... minimum wage, assure the wage floor does not erode again, and make future increases more ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty ... Barry M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... and the most handsome men, look naturally attractive. Plastic surgery should be invisible.” ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... with extensive sequencing and genomics experience, as Vice President of North American Capital Sales ... be responsible for leading the sales team in the commercialization of the HTG EdgeSeq ...
Breaking Medicine News(10 mins):